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Abstract
Although more than 20 genetic susceptibility loci have been reported for type 2 diabetes (T2D), most reported variants have
small to moderate effects and account for only a small proportion of the heritability of T2D, suggesting that the majority of
inter-person genetic variation in this disease remains to be determined. We conducted a multistage, genome-wide
association study (GWAS) within the Asian Consortium of Diabetes to search for T2D susceptibility markers. From 590,887
SNPs genotyped in 1,019 T2D cases and 1,710 controls selected from Chinese women in Shanghai, we selected the top
2,100 SNPs that were not in linkage disequilibrium (r
2,0.2) with known T2D loci for in silico replication in three T2D GWAS
conducted among European Americans, Koreans, and Singapore Chinese. The 5 most promising SNPs were genotyped in an
independent set of 1,645 cases and 1,649 controls from Shanghai, and 4 of them were further genotyped in 1,487 cases and
3,316 controls from 2 additional Chinese studies. Consistent associations across all studies were found for rs1359790
(13q31.1), rs10906115 (10p13), and rs1436955 (15q22.2) with P-values (per allele OR, 95%CI) of 6.49610
29 (1.15, 1.10–1.20),
1.45610
28 (1.13, 1.08–1.18), and 7.14610
27 (1.13, 1.08–1.19), respectively, in combined analyses of 9,794 cases and 14,615
controls. Our study provides strong evidence for a novel T2D susceptibility locus at 13q31.1 and the presence of new
independent risk variants near regions (10p13 and 15q22.2) reported by previous GWAS.
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Introduction
Type 2 diabetes (T2D) is a common complex disease that affects
over a billion people worldwide [1]. Through genome-wide
association studies (GWAS), at least 24 genetic susceptibility loci
have been reported for T2D [1–9], including a SNP, rs7593730, at
2q24 near the RBMS1 and ITGB6 genes that was associated with
diabetes risk in a recent report from the Nurses’ Health Study/
Health Professionals Follow-up Study (NHS/HPFS) [2]. However,
most of the reported genetic variants have small to moderate
effects and account for only a small proportion of the heritability of
T2D, suggesting that the majority of inter-person genetic variation
in this disease remains to be determined. Over the last two
decades, China, like many other Asian countries, has experienced
a dramatic increase in T2D incidence. Cumulative evidence
suggests that Asians may be more susceptible to insulin resistance
compared with populations of European ancestry [10]. However,
among the previously reported T2D genetic markers, only three
SNPs – including two reported very recently – have been identified
in populations of Asian ancestry [8,9]. SNP rs2283228 in the
PLoS Genetics | www.plosgenetics.org 1 September 2010 | Volume 6 | Issue 9 | e1001127KCNQ1 gene was identified in a 3-stage study that included 194
diabetes patients and 1,558 controls and 268,068 SNPs in the first
(discovery) stage [8]. A study conducted among Han Chinese in
Taiwan recently identified two additional novel loci in the protein
tyrosine phosphatase receptor type D (PTPRD; P=8.54610
210)
and serine racemase (SRR; P=3.06610
29) genes [9].
Large genetic studies conducted in Asian populations will
facilitate the identification of additional genetic markers for T2D,
particularly for markers with a higher frequency in Asians than in
other populations. We recently completed a GWAS of T2D in
Shanghai. We report here our first effort, using a fast-track,
multiple-stage study approach, to identify novel genetic markers
for diabetes.
Methods
Ethics statement
The study protocol was approved by the institutional review
boards at Vanderbilt University Medical Center and at each of the
collaborating institutes. Informed consent was obtained from all
participants.
Study design and population
This study consisted of a discovery stage and two validation
stages, i.e. an in silico and a de novo validation study. The overall
study design is presented in Figure S1.
The discovery stage included 1,019 T2D cases, 886 incident
T2D cases from the Shanghai Women’s Health Study (SWHS), an
ongoing, population-based, prospective cohort study of women
living in Shanghai, and 133 prevalent T2D cases identified among
controls of the Shanghai Breast Cancer Study (SBCS), who were
recruited in Shanghai during approximately the same period as
the SWHS [11]. Controls for the discovery phase were 1,710 non-
diabetic female controls from the SBCS (for further details, see
Text S1, online). The biologic samples used for genotyping in this
study were collected by the SWHS and SBCS.
Genotyping and quality control procedures
DNA samples were genotyped using the Affymetrix Genome-
Wide Human SNP Array 6.0. Extensive quality control (QC)
procedures were implemented in the study. In the SWHS/SBCS
GWAS scan, three positive QC samples purchased from Coriell
Cell Repositories and a negative QC sample were included in each
of the 96-well plates of the Affymetrix SNP Array 6.0. SNP data
obtained from positive quality control samples showed a very high
concordance rate of called genotypes based on 79,764,872
comparisons (mean, 99.87%; median, 100%). Samples with
genotyping call rates less than 95% were excluded. The sex of
all study samples was confirmed to be female. The identity-by-
descent analysis based on identity by state was performed to detect
first-degree cryptic relationships using PLINK version 1.06 [12].
We excluded from the study 21 samples that had: 1) call rate
,95% (n=5); 2) samples that were contaminated or had mixed-
up labels or that had been duplicated (n=12); 3) first-degree
relatives, such as parent-offspring or full siblings (n=4).
We also excluded from the analysis SNPs that met any of
following criteria: 1) MAF ,0.05; 2) call rate ,95%; 3) P for
Hardy-Weinburg equilibrium HWE ,0.00001 in either the case
or control groups or in the combined data set; 4) concordance rate
,95% among the duplicated QC samples; 5) significant difference
in allele frequency distribution (P,0.00001) between the 886 T2D
cases from the SWHS and the 133 T2D cases from the SBCS; 6)
significant difference in missing rates between cases and controls
(P,0.00001). After applying the QC filter, 590,887 SNPs
remained for the analyses.
Because of financial constraints, we conducted a fast-track
validation study using an approach that combined in silico and de
novo replication. We selected a total of 2,100 SNPs from the
discovery phase that had P-values of 1.3610
29 to 5.0610
23
derived from the additive model and that were not in linkage
disequilibrium (LD; r
2,0.2 based on the HapMap CHB dataset)
with any previously reported T2D GWAS SNPs for an in silico
replication using the GWAS scan data from the NHS/HPFS [2].
We used the NHS/HPFS T2D GWAS scans for our first step of
validation, because the Shanghai T2D GWAS was conducted
concurrently and used the same genotyping platform as the NHS/
HPFS T2D GWAS and a priori arrangement was made for the two
studies to exchange the top 2,000 SNPs for in silico replication. The
NHS/HPFS T2D GWAS included 2,591 cases and 3,052 controls
of European ancestry. We recognize that this approach may have
reduced our chances of finding ethnicity-specific T2D markers,
however, this approach had the advantage of enhancing our
ability of finding true genetic markers. From the first in silico
replication, 65 SNPs with the same direction of association in both
studies and with a MAF .20% were chosen for a second in silico
replication using GWAS scan data from a Korean T2D study,
which included 1,042 cases and 2,943 controls genotyped with the
Affymetrix Genome-Wide Human SNP Array 5.0 platform. In
order to improve yield, only the top SNPs that are included in
Affymetrix 5.0 (N=56) or that are in high LD (r
2.0.8) with at
least one SNP on Affymetrix 5.0 (N=9) were selected for
replication (Table S1). Of the 65 SNPs, the top 8 SNPs replicated
in the Korean T2D study were further investigated using GWAS
data from a T2D study conducted among Singapore Chinese
(2,010 cases and 1,945 controls) who were genotyped by using
Illumina HumanHap 610 or Illumina Human1M (Table S2). Four
of the 8 SNPs were not directly genotyped in the Singapore study,
so instead, we selected SNPs that are in strong LD with these 4
SNPs (imputed SNP information became available recently and is
presented in this report). Finally, the 5 top SNPs (rs2815429,
rs10906115, rs1359790, rs10751301, and rs1436955) were
selected for de novo genotyping in an independent sample set of
1,645 T2D cases and 1,649 controls identified from the SWHS
and Shanghai Men’s Health Study (SMHS). Four of these SNPs
(rs10906115, rs1359790, rs10751301, and rs1436955) were
selected for the final stage of de novo genotyping replication in
two independent Chinese studies, the Wuhan Diabetes Study
(WDS; 1,063 cases and 1,408 controls) and the Nutrition and
Author Summary
Type 2 diabetes, a complex disease affecting more than a
billion people worldwide, is believed to be caused by both
environmental and genetic factors. Although some studies
have shown that certain genes may make some people
more susceptible to type 2 diabetes than others, the genes
reported to date have only a small effect and account for a
small proportion of type 2 diabetes cases. Furthermore,
few of these studies have been conducted in Asian
populations, although Asians are known to be more
susceptible to insulin resistance than people living in
Western countries, and incidence of type 2 diabetes has
been increasing alarmingly in Asian countries. We con-
ducted a multi-stage study involving 9,794 type 2 diabetes
cases and 14,615 controls, predominantly Asians, to
discover genes related to susceptibility to type 2 diabetes.
We identified 3 genetic regions that are related to
increased risk of type 2 diabetes.
Type 2 Diabetes Genetic Risk Variants
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and 1,908 controls). Detailed descriptions of the study designs and
populations for each of the participating studies are presented in
Text S1 online.
Genotyping for the 5 SNPs included in the SWHS and SMHS
sample set was completed using the iPLEX Sequenom MassArray
platform. Included in each 96-well plate as quality control samples
were two negative controls, two blinded duplicates, and two
samples included in the HapMap project. We also included 65
subjects who had been genotyped by the Affymetrix SNP Array
6.0 in the Sequenom genotyping. The consistency rate was 100%
for all SNPs for the blinded duplicates, compared with the
HapMap data and compared with data from the Affymetrix SNP
Array 6.0. Genotyping for the final 4 SNPs in the WDS and
NHAPC was completed using TaqMan assays at the two local
institute laboratories using reagents provided by the Vanderbilt
Molecular Epidemiology Laboratory. Both laboratories were
asked to genotype a trial plate provided by the Vanderbilt
Molecular Epidemiology Laboratory that contained DNA from 70
Chinese samples before the main study genotyping was conducted.
The consistency rates for these trial samples were 100% compared
with genotypes previously determined at Vanderbilt for all four
SNPs in both local laboratories. In addition, replicate samples
comparing 3–7% of all study samples were dispersed among
genotyping plates for both studies.
Imputation
The imputation of un-genotyped SNPs in all participating
GWASs was carried out after the completion of the current study
using the programs MACH (http://www.sph.umich.edu/csg/
abecasis/MACH/) or IMPUTE (https://mathgen.stats.ox.ac.uk/
impute) with HapMap Asian data as the reference for Asians and
CEU data as the reference for European-ancestry samples. Only
data with high imputation quality (RSQR .0.3 for MACH) were
included in the current analysis.
Statistical analyses
PLINK version 1.06 was used to analyze genome-wide data
obtained in the SBCS/SWHS GWAS scan. Population structure
was evaluated by principal component analysis using EIGEN-
STRAT(http://genepath.med.harvard.edu/,reich/Software.htm).
A set of 12,533 SNPs with a MAF $10% in Chinese samples and a
distance of $25 kb between two adjacent SNPs was selected to
evaluate the population structure. The first two principal compo-
nents were included in the logistic regression models for adjustment
of population structures. The inflation factor l was estimated to be
1.03, suggesting that population substructure, if present, should not
have any appreciable effect on the results.
Pooled and meta-analyses were carried out in SAS to derive
combined odds ratios (OR) by using data from studies of all stages.
We applied the weighted z-statistics method, where weights are
proportional to the square root of the number of subjects in each
study. Results from both random and fixed effect models are
presented.
ORs and 95% confidence intervals (CI) were estimated using
logistic regression models with adjustment for age, BMI,
population structure (for GWAS data), and gender, when
appropriate. Analyses with additional adjustment for smoking
were conducted by pooled analysis whenever possible and by
meta-analysis when KARE data were included in order to
examine the confounding and modification effects of these factors
(Table S2). Genotype distributions for the top 4 SNPs included in
the final de novo genotyping were consistent with HWE (P. 0.05) in
each study. All P values presented are based on two-tailed tests,
except where indicated otherwise.
Results
The general characteristics of the participating study popula-
tions are presented in Table 1. T2D cases had a higher BMI than
controls across all studies. Except for the SWHS, SMHS, and
Shanghai Nutrition Institute (SNI) validation studies, where cases
and controls were matched on age, cases were older than controls
in all other studies. A difference in gender distribution was also
seen in several studies. These variables were adjusted for in
subsequent analyses.
Table 2 presents the results of analyses of associations of T2D
with previously reported, GWAS-identified genetic markers in our
discovery samples [1–9]. Of the 24 SNPs reported by previous
GWAS, 15 were directly genotyped by the Affymetrix SNP Array
6.0. One SNP (rs7578597) showed a MAF=0 in HapMap CHB
data and was not included on the Affymetrix 6.0 chip. The
remaining 8 SNPs, including rs2943641, rs10010131, rs13266634,
rs12779790, and rs4430796, as well as the newly identified
markers rs391300 and rs17584499, were imputed. SNP rs4430796
showed low imputation quality (RSQR=0.06) in the SBCS/
SWHS GWAS and was excluded from the analysis.
Table 1. Characteristics of the study participants.
Study population Cases Controls % Men Age
a BMI
a
Study area N=9,794 N=14,615 Cases Controls Cases Controls Cases Controls
Discovery Stage SBCS/SWHS Shanghai
b 1019 1710 0.0 0.0 51.766.7 48.768.5 26.563.7 23.163.3
Replication Set I NHS/HPFS USA 2591 3052 43.4 42.5 54.267.6 53.967.5 27.664.6 24.163.6
KARE Korea 1042 2943 51.7 46.0 56.468.6 51.168.6 25.563.3 24.162.9
SDCS/SP2 Singapore
c 2010 1945 50.0 42.0 64.4610.2 47.2610.7 25.363.9 22.663.6
Replication Set II SWHS/SMHS Shanghai
b 1645 1649 44.6 44.5 58.968.8 58.968.7 26.363.5 24.263.4
NHAPC Shanghai/
Beijing
b
424 1908 48.8 41.5 59.765.7 58.466.0 25.463.5 23.863.4
WDS Wuhan
b 1063 1408 57.6 58.7 50.7610.4 42.8610.0 24.863.7 23.063.1
aAge and BMI are presented as mean 6 SD.
bConducted in China and included Chinese participants only.
cOnly Chinese participants were included.
doi:10.1371/journal.pgen.1001127.t001
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with initial reports at P,0.05, including rs4402960 (3q27.2,
IGF2BP2), rs10946398 (6p22.3, CDKAL1), rs13266634 (8q24.11,
SLC30A8), rs10811661 (9p21.3, CDKN2A/B), rs5015480
(10q23.33, HHEX), rs7901695 (10q25.2, TCF7L2), rs2283228
(11p15.5, KCNQ1), and rs5215 (11p15.1, KCNJ11). Among the
Table 2. Associations of previously-reported T2D related SNPs with disease risk in Chinese women.
Risk allele
frequency
SNP
a Region Alleles
b Gene Genotyping
c Cases Controls OR (95% CI)
d
Pf o r
trend
e
Reported
Effect
Power to
detect
association
f
rs10923931 [1] 1p12 T/G NOTCH2,ADAM30 Affy 6.0 0.03 0.03 1.02 (0.71–1.48) 0.454 1.13
(1.08–1.17)
0.19
rs2943641 [3] 2q36.3 C/T LOC64673/IRS1 Imputed 0.93 0.93 1.20 (0.94–1.54) 0.070 1.19
(1.13–1.25)
0.45
rs1801282 [1] 3p25.2 C/G PPARG Affy 6.0 0.94 0.95 0.99 (0.76–1.30) 0.523 1.14
(1.08–1.20)
0.25
rs4607103 [1] 3p14.1 C/T ADAMTS9 Affy 6.0 0.62 0.63 1.03 (0.91–1.17) 0.302 1.09
(1.06–1.12)
0.43
rs4402960 [6] 3q27.2 T/G IGF2BP2 Affy 6.0 0.28 0.24 1.28 (1.12–1.49) 2.4610
24 1.14
(1.11–1.18)
0.65
rs10010131 [4] 4p16.1 G/A WFS1 Imputed 0.95 0.95 0.95 (0.71–1.28) 0.632 1.11
(1.05–1.16)
0.19
rs10946398 [6] 6p22.3 C/A CDKAL1 Affy 6.0 0.45 0.41 1.20 (1.06–1.36) 0.002 1.14
(1.11–1.17)
0.75
rs864745 [1] 7p15.1 T/C JAZF1 Affy 6.0 0.78 0.78 0.97 (0.84–1.13) 0.637 1.10
(1.07–1.13)
0.40
rs13266634 [7] 8q24.11 C/T SLC30A8 Imputed 0.61 0.58 1.19 (1.04–1.35) 0.004 1.15
(1.12–1.19)
0.79
rs10811661 [6] 9p21.3 T/C CDKN2A/B Affy 6.0 0.56 0.52 1.24 (1.10–1.40) 3.05610
24 1.20
(1.14–1.25)
0.95
rs564398 [5] 9p21.3 T/C CDKN2B Affy 6.0 0.89 0.88 1.08 (0.89–1.31) 0.209 1.12
(1.07–1.17)
0.36
rs12779790 [1] 10p13 G/A CDC123,CAMK1D Imputed 0.17 0.17 1.04 (0.88–1.23) 0.309 1.11
(1.07–1.14)
0.42
rs5015480 [1] 10q23.33 C/T HHEX Affy 6.0 0.20 0.17 1.42 (1.20–1.66) 9.1610
26 1.17
(1.11–1.24)
0.70
rs7901695 [7] 10q25.2 C/T TCF7L2 Affy 6.0 0.04 0.03 1.41 (1.03–1.93) 0.017 1.37
(1.31–1.43)
0.67
rs2283228 [8] 11p15.5 C/T KCNQ1 Affy 6.0 0.66 0.62 1.16 (1.03–1.30) 0.003 1,26
(1.18–1.34)
0.96
rs5215 [4] 11p15.1 C/T KCNJ11 Affy 6.0 0.42 0.38 1.21 (1.07–1.37) 0.001 1.14
(1.10–1.19)
0.74
rs1495377 [5] 12q15 G/C NR Affy 6.0 0.27 0.27 0.97 (0.84–1.11) 0.683 1.12
(1.06–1.18)
0.57
rs7961581 [1] 12q21.1 C/T TSPAN8,LGR5 Affy 6.0 0.20 0.21 0.96 (0.82–1.12) 0.708 1.09
(1.06–1.12)
0.36
rs8050136 [6] 16q12.2 A/C FTO Affy 6.0 0.13 0.12 0.98 (0.81–1.19) 0.574 1.17
(1.12–1.22)
0.60
rs391300 [9] 17p13.3 C/T SRR Imputed 0.71 0.72 0.96 (0.83–1.10) 0.739 1.28
(1.18–1.39)
0.99
rs17584499 [9] 9p24.1 T/C PTPRD Imputed 0.10 0.10 0.97 (0.71–1.32) 0.575 1.57
(1.13–1.83)
1.00
rs7593730 [2] 2q24.2 T/C RBMS1/ITGB6 Affy 6.0 0.82 0.84 0.96 (0.82–1.14) 0.331 1.11
(1.08–1.16)
0.40
aTwo SNPs were not included in the current analysis because of poor imputation quality (RSQR=0.06 for rs4430796) or a very low MAF in the Chinese population
(rs7578597 MAF=0 in HapMap CHB samples).
bRisk allele/reference allele initially reported (based on forward strand).
cFor imputed SNPs, dosage data with imputation uncertainty taken into account were used to evaluate the association.
dResults were derived from analysis of 1,019 cases and 1,710 controls with adjustment for age, BMI, and two major principal components.
eOne-tailed p-values.
fThe power was estimated under the additive model and given the reported effect size, 1,019 cases, 1,710 controls, and a=0.05 (one-sided).
doi:10.1371/journal.pgen.1001127.t002
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population. Thus, our study did not have sufficient statistical
power (statistical power range: 19–45%) to replicate these markers
(Table 2). Associations of T2D with SNPs that are in LD with the
reported T2D SNPs discovered in European-ancestry populations
or in Asians are presented in Table S3.
Multidimensional scaling analyses of the GWAS scan data
showed no evidence of apparent genetic admixture in our study
population (Figure S2). The observed number of SNPs with a
small P value was larger than expected by chance (Figure S3). We
found that rs10906115 (10p13), rs1359790 (13q31.1), and
rs1436955 (15q22.2) were consistently associated with T2D across
all studies, although the 95% CI for the per allele ORs in several
studies included 1.0 (Table 3; Figure 1). P-values for trend tests
(per allele OR, 95% CI) from meta-analyses of data from all
studies were highly statistically significant for these associations:
1.45610
28 for rs10906115 (1.13, 1.08–1.18), 6.49610
29 for
rs1359790 (1.15, 1.10–1.20), and 7.14610
27 for rs1436955 (1.13,
1.08–1.19). These P-values were below (for rs1359790 and
rs10906115) or near (for rs1436955) the genome-wide significance
level of 5.0610
28. SNP rs10751301 (11q14.1) was not replicated
in the Singapore or de novo genotyping studies; the P-value for the
meta-analysis was 1.31610
24 in the fixed effect model and 0.004
in the random effect model. Additional adjustment for smoking
history did not appreciably change the point estimates described
above, although the P-values were slightly elevated (Table S2).
In an exploratory analysis stratified by smoking, BMI, family
history of T2D, and age at diagnosis, SNP rs1359790 showed a
slightly stronger association with T2D risk among non-smokers
(per allele OR=1.19, 95% CI=1.12–1.26, P=6.4610
28) than
among smokers (OR=1.09, 95% CI=1.00–1.19, P=0.044) with
a P value of 0.11 for interaction (Table S4). None of the SNPs
were related to age at onset of T2D. Neither family history of T2D
nor BMI altered the SNP-T2D associations under study.
Discussion
Using the GWAS data from our discovery stage samples, we
were able to validate 8 of 22 previously reported, GWAS-identified
T2D SNPs, lending strong support to the validity of the initial
discovery samples and methodologies. Applying a fast-track
validation study approach, we also identified three promising
new T2D markers.
The most significant association identified by our study was for
rs1359790 (13q13.1), a novel genetic susceptibility locus identified
for T2D (Figure 2). Several transcription factors, such as NIT-2,
Table 3. Associations of T2D risk with the top four SNPs by study phase.
Number Frequency
b OR(95% CI)
c
SNP Region Alleles
a Study Set Cases Controls Cases Controls Per allele P for trend
rs10906115 10p13 A/G GWA scan 1019 1710 0.65 0.62 1.20 (1.05–1.36) 0.007
Replication Set I
d 5613 7918 0.60 0.57 1.10 (1.03–1.16) 0.002
Replication Set II 3115 4944 0.65 0.62 1.17 (1.09–1.18) 1.95610
25
Fixed model 1.13 (1.08–1.18) 1.45610
28
Random model 1.13 (1.08–1.18) 1.45610
28
Homogeneity test P=0.618
rs1359790 13q31.1 G/A GWA scan 1009 1690 0.75 0.71 1.22 (1.06–1.40) 0.006
Replication Set I
d 5604 7864 0.73 0.71 1.10 (1.04–1.18) 0.002
Replication Set II 3117 4907 0.74 0.71 1.20 (1.11–1.29) 6.19610
26
Fixed model 1.15 (1.10–1.20) 6.49610
29
Random model 1.15 (1.10–1.20) 6.49610
29
Homogeneity test P=0.665
rs1436955 15q22.2 C/T GWA scan 1019 1709 0.79 0.75 1.22 (1.05–1.42) 0.008
Replication Set I
d 5642 7938 0.77 0.73 1.13 (1.06–1.21) 2.41610
24
Replication Set II 3126 4944 0.78 0.76 1.10 (1.01–1.19) 0.024
Fixed model 1.13 (1.08–1.19) 7.14610
27
Random model 1.13 (1.08–1.19) 7.14610
27
Homogeneity test 0.739
rs10751301 11q14.1 C/G GWA scan 1018 1710 0.24 0.21 1.23 (1.06–1.42) 0.006
Replication Set I
d 5536 7579 0.37 0.33 1.13 (1.06–1.21) 9.09610
25
Replication Set II 3123 4938 0.22 0.21 1.01 (0.93–1.10) 0.863
Fixed model 1.10 (1.05–1.15) 1.31610
24
Random model 1.09 (1.03–1.16) 0.004
Homogeneity test P=0.199
Notes:
aBold alleles are risk alleles.
bFrequency of risk alleles.
cAdjusted for age, gender, BMI, two major principal components, and study site when appropriate.
dDerived from meta-analysis.
doi:10.1371/journal.pgen.1001127.t003
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to T transition eliminates a GATA-2 binding site and creates a
TATA binding site. The closest known gene, sprouty homolog 2
(Drosophila) (SPRY2), is located 193 kb upstream of rs1359790.
The SPRY2 gene encodes a protein belonging to the sprouty family
and inhibits growth factor-mediated, receptor tyrosine kinase-
induced, mitogen-activated protein kinase signaling [13]. The
encoded protein contains a carboxyl-terminal cysteine-rich
domain essential for the inhibitory activity of receptor tyrosine
kinase signaling proteins and is required for growth factor-
stimulated translocation of the protein to membrane ruffles
[13,14]. SPRY2 also modulates the apoptotic actions induced by
the pro-inflammatory cytokine, tumor necrosis factor-alpha [15].
SPRY4, a homolog of SPRY2, inhibits the insulin receptor-
Figure 1. Forest plot for per-allele ORs for the association of T2D risk with 4 SNPs in all participating studies.
doi:10.1371/journal.pgen.1001127.g001
Figure 2. Association signals at four chromosome regions. Results (-logP) are shown for directly genotyped (blue diamonds) and imputed
(white circles) SNPs for a 1Mb region centered on the SNP of interest. Gene locations are from the March 2006 UCSC genome browser assembly.
doi:10.1371/journal.pgen.1001127.g002
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ment of the pancreas [17].
SNP rs10906115 is located on chromosome 10p13 (Figure 2),
13.0 kb from rs12779790, which was reported by a previous
GWAS of T2D [1]. These two SNPs, however, are in low LD in
both Chinese (r
2=0.06) and European populations (r
2=0.19)
based on HapMap data. SNP rs12779790 was not included in the
Affymetrix SNP Array 6.0, Illumina HumanHap 610-Quad, or
Human1M-Duo; thus, it was imputed for both the SBCS/SWHS
and the NHS/HPFS by using MACH with RSQR.0.9 and for
the Singapore studies using IMPUTE with PROPER_INFO
.0.85. The imputed SNP rs12779790 was associated with a per
allele OR of 1.10 (95% CI=1.01–1.19, P=0.035) in the analysis
of pooled data from three studies. However, when both
rs12779790 and rs10906115 were included in the same logistic
model, the association with rs10906115 remained statistically
significant (per allele OR=1.09, 95% CI=1.02–1.16, P=0.007),
while the association with rs12779790 was no longer statistically
significant (per allele OR=1.04 [95% CI=0.96–1.12], P=0.38;
Table 4). These data provide strong evidence that rs10906115 is a
new genetic variant at 10p13 independent of the previously-
identified SNP rs12779790.
SNP rs10906115 is located 22.4 kb downstream of the cell
division-cycle 123 homolog (S. cerevisiae) (CDC123) gene and
76.6 kb upstream of the calcium/calmodulin-dependent protein
kinase ID (CAMK1D) gene (Figure 2). The CDC123 gene encodes a
protein involved in cell cycle regulation and nutritional control of
gene transcription [18]. The CAMK1D gene encodes a member of
the Ca2+/calmodulin-dependent protein kinase 1 subfamily of
serine/threonine kinases. The encoded protein may be involved in
the regulation of granulocyte function through the chemokine
signal transduction pathway [19]. The role of the CDC123 and
CAMK1D genes in the etiology of T2D is unclear.
SNP rs1436955, located on chromosome 15q22.2 (Figure 2), is
51.4 kb downstream of a C2 calcium-dependent domain contain-
ing the 4B gene (C2CD4B; also known as NLF2 or FAM148B).
C2CD4B is up-regulated by pro-inflammatory cytokines and may
play a role in regulating genes that control cellular architecture
[20]. The role of inflammation in the pathophsyiology of T2D has
been suggested previously [21–25]. C2CD4B and SPRY2 are both
highly expressed in human pancreatic tissue [26]. Intriguingly, a
very recent report from the Meta-Analysis of Glucose and Insulin-
related traits Consortium (MAGIC) found that a SNP
(rs11071657) near the C2CD4B gene was associated with fasting
glucose (P=3.6610
28) and T2D (P=2.9610
23) [27]. SNPs
rs11071657 and rs1436955, however, are not in LD (r
2=0.04)
in Asians, although they are weakly related (r
2=0.25) in
Europeans, according to HapMap data. SNP rs11071657 is not
included in the Affymetrix SNP 6.0 array. Imputed data from the
SBCS/SWHS GWAS showed that this SNP was not significantly
associated with T2D risk (per A allele OR=1.06, 95% CI=0.94–
1.19), although the direction of the association was consistent with
that reported by the MAGIC consortium [27]. Adjusting for
rs11071657 did not alter the association of T2D risk with
rs1436955 (per allele OR=1.21, 95% CI=1.06–1.39,
P=0.006). Again, these data strongly imply that rs1436955 may
be a new genetic risk variant for T2D at 15q22.2 independent of
the recently reported SNP rs11071657.
In summary, in this first GWAS of T2D conducted in a Chinese
population, we identified a novel genetic susceptibility locus for
T2D, rs1359790, at 13q31.1. Furthermore, we revealed two new
genetic variants (rs10906115 at 10p13 and rs1436955 at15q22.2)
near T2D susceptibility loci previously reported by GWAS of T2D
conducted in European-ancestry populations. Our study demon-
strates the value of conducting GWAS in non-European
populations for the identification of novel genetic susceptibility
markers for T2D.
Supporting Information
Table S1 Association of 65 SNPs included in Replication Set I
with T2D risk.
Table 4. Association of SNPs rs10906115 and rs12779790 with type 2 diabetes.
SNP Study OR (95% CI)
a P
rs10906115 Without adjustment for rs12779790 SBCS/SWHS 1.20 (1.05–1.36) 0.007
NHS/HPFS 1.10 (1.02–1.20) 0.020
Singapore 1.02 (0.90–1.16) 0.74
Combined
b 1.10 (1.04–1.17) 5.0610
24
With adjustment for rs12779790 SBCS/SWHS 1.21 (1.05–1.38) 0.007
NHS/HPFS 1.07 (0.98–1.17) 0.16
Singapore 1.01 (0.88–1.16) 0.86
Combined
b 1.09 (1.02–1.16) 0.007
rs12779790 Without adjustment for rs10906115 SBCS/SWHS 1.05 (0.90–1.23) 0.54
NHS/HPFS 1.16 (1.04–1.28) 0.006
Singapore 1.04 (0.89–1.23) 0.63
Combined
b 1.10 (1.01–1.19) 0.035
With adjustment for rs10906115 SBCS/SWHS 0.97 (0.82–1.15) 0.73
NHS/HPFS 1.12 (1.01–1.25) 0.048
Singapore 1.04 (0.87–1.23) 0.69
Combined
b 1.04 (0.96–1.12) 0.38
aAdjusted for age, gender, BMI, and two major principal components.
bDerived from meta-analysis.
doi:10.1371/journal.pgen.1001127.t004
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associations with T2D stratified by smoking, BMI, family history
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DOC)
Figure S1 Study design.
Found at: doi:10.1371/journal.pgen.1001127.s005 (0.09 MB TIF)
Figure S2 MDS analyses to confirm all subjects were Asians.
Found at: doi:10.1371/journal.pgen.1001127.s006 (1.55 MB TIF)
Figure S3 QQ Plot.
Found at: doi:10.1371/journal.pgen.1001127.s007 (9.73 MB TIF)
Text S1 Supplementary Methods.
Found at: doi:10.1371/journal.pgen.1001127.s008 (0.13 MB
DOC)
Acknowledgments
The content is solely the responsibility of the authors and does not
necessarily represent the official views of the NIH. The authors wish to
thank the study participants and research staff for their contributions and
commitment to this project, R. Courtney, R. Gal-Chis, and the late
Q. Wang for DNA preparation, J. He for technical support in graphics
presentation, and B. Hull for clerical support in the preparation of this
manuscript.
Author Contributions
Conceived and designed the experiments: XOS QC WZ FBH. Performed
the experiments: QC JS. Analyzed the data: JL WW YJK CL. Contributed
reagents/materials/analysis tools: JL QC LQ YBX YSC EST XL XL
WHC MJG MS WB HL MCC KY BGH XLS LL QQ HLK DPKN JYL
YTG WZ FBH. Wrote the paper: XOS JL QC WZ.
References
1. Zeggini E, Scott LJ, Saxena R, Voight BF, Marchini JL, et al. (2008) Meta-
analysis of genome-wide association data and large-scale replication identifies
additional susceptibility loci for type 2 diabetes. Nat Genet 40: 638–645.
2. Qi L, Cornelis MC, Kraft P, Stanya KJ, Kao WHL, et al. (2010) Genetic
variants at 2q24 are associated with susceptibility to type 2 diabetes. Hum Mol
Genet 19: 2706–2715.
3. Rung J, Cauchi S, Albrechtsen A, Shen L, Rocheleau G, et al. (2009) Genetic
variant near IRS1 is associated with type 2 diabetes, insulin resistance and
hyperinsulinemia. Nat Genet 41: 1110–1115.
4. Frayling TM (2007) Genome-wide association studies provide new insights into
type 2 diabetes aetiology. Nat Rev Genet 8: 657–662.
5. Zeggini E, Weedon MN, Lindgren CM, Frayling TM, Elliott KS, et al. (2007)
Replication of genome-wide association signals in UK samples reveals risk loci
for type 2 diabetes. Science 316: 1336–1341.
6. Scott LJ, Mohlke KL, Bonnycastle LL, Willer CJ, Li Y, et al. (2007) A genome-
wide association study of type 2 diabetes in Finns detects multiple susceptibility
variants. Science 316: 1341–1345.
7. Sladek R, Rocheleau G, Rung J, Dina C, Shen L, et al. (2007) A genome-wide
association study identifies novel risk loci for type 2 diabetes. Nature 445:
881–885.
8. Unoki H, Takahashi A, Kawaguchi T, Hara K, Horikoshi M, et al. (2008) SNPs
in KCNQ1 are associated with susceptibility to type 2 diabetes in East Asian and
European populations. Nat Genet 40: 1098–1102.
9. Tsai FJ, Yang CF, Chen CC, Chuang LM, Lu CH, et al. (2010) A genome-wide
association study identifies susceptibility variants for type 2 diabetes in Han
Chinese. PLoS Genet 6: e1000847.
10. Chan JC, Malik V, Jia W, Kadowaki T, Yajnik CS, et al. (2009) Diabetes in
Asia: epidemiology, risk factors, and pathophysiology. JAMA 301: 2129–2140.
11. Zheng W, Long J, Gao YT, Li C, Zheng Y, et al. (2009) Genome-wide
association study identifies a new breast cancer susceptibility locus at 6q25.1. Nat
Genet 41: 324–328.
12. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, et al. (2007)
PLINK: a tool set for whole-genome association and population-based linkage
analyses. Am J Hum Genet 81: 559–575.
13. Cabrita MA, Christofori G (2008) Sprouty proteins, masterminds of receptor
tyrosine kinase signaling. Angiogenesis 11: 53–62.
14. Guy GR, Jackson RA, Yusoff P, Chow SY (2009) Sprouty proteins: modified
modulators, matchmakers or missing links? J Endocrinol 203: 191–202.
15. Ding W, Warburton D (2008) Down-regulation of Sprouty2 via p38 MAPK
plays a key role in the induction of cellular apoptosis by tumor necrosis factor-
alpha. Biochem Biophys Res Commun 375: 460–464.
16. Leeksma OC, Van Achterberg TA, Tsumura Y, Toshima J, Eldering E, et al.
(2002) Human sprouty 4, a new ras antagonist on 5q31, interacts with the dual
specificity kinase TESK1. Eur J Biochem 269: 2546–2556.
17. Jaggi F, Cabrita MA, Perl AK, Christofori G (2008) Modulation of endocrine
pancreas development but not beta-cell carcinogenesis by Sprouty4. Mol Cancer
Res 6: 468–482.
18. P, Shilinski K, Tsichlis PN, Brenner C (2004) Cdc123 and checkpoint forkhead
associated with RING proteins control the cell cycle by controlling eIF2gamma
abundance. J Biol Chem 279: 44656–44666.
19. Verploegen S, Ulfman L, van Deutekom HW, van Aalst C, Honing H, et al.
(2005) Characterization of the role of CaMKI-like kinase (CKLiK) in human
granulocyte function. Blood 106: 1076–1083.
20. Warton K, Foster NC, Gold WA, Stanley KK (2004) A novel gene family
induced by acute inflammation in endothelial cells. Gene 342: 85–95.
21. Goldberg RB (2009) Cytokine and cytokine-like inflammation markers,
endothelial dysfunction, and imbalanced coagulation in development of diabetes
and its complications. J Clin Endocrinol Metab 94: 3171–3182.
22. Surampudi PN, John-Kalarickal J, Fonseca VA (2009) Emerging concepts in the
pathophysiology of type 2 diabetes mellitus. Mt Sinai J Med 76: 216–226.
23. Ray A, Huisman MV, Tamsma JT, van AJ, Bingen BO, et al. (2009) The role of
inflammation on atherosclerosis, intermediate and clinical cardiovascular
endpoints in type 2 diabetes mellitus. Eur J Intern Med 20: 253–260.
24. King GL (2008) The role of inflammatory cytokines in diabetes and its
complications. J Periodontol 79: 1527–1534.
25. Moller DE, Berger JP (2003) Role of PPARs in the regulation of obesity-related
insulin sensitivity and inflammation. Int J Obes Relat Metab Disord 27 Suppl 3:
S17–S21.
26. Yanai I, Benjamin H, Shmoish M, Chalifa-Caspi V, Shklar M, et al. (2005)
Genome-wide midrange transcription profiles reveal expression level relation-
ships in human tissue specification. Bioinformatics 21: 650–659.
27. Dupuis J, Langenberg C, Prokopenko I, Saxena R, Soranzo N, et al. (2010) New
genetic loci implicated in fasting glucose homeostasis and their impact on type 2
diabetes risk. Nat Genet.
Type 2 Diabetes Genetic Risk Variants
PLoS Genetics | www.plosgenetics.org 8 September 2010 | Volume 6 | Issue 9 | e1001127